PFE

Healthcare / Pharmaceuticals & Biotechnology
Global biopharmaceutical company generating revenue through R&D, manufacturing, and commercialization of prescription drugs, vaccines, biologics, and biosimilars across multiple therapeutic areas.
Recommended: koller_dcf
$24.17
Current market price
Source: FMP +EDGAR

Market implications

What the market is baking into $24.17. Does not change with your assumptions.

Implied terminal growth (cv_g)
-1.61%
solved so market model = $24.17 with the analyst inputs below
WACC (CAPM)
5.17%
β: 0.31 · Rf: 4.0% · ERP: 5.5%
Ke: 5.69% · Kd(AT): 4.10%
E/V: 67.1% · D/V: 32.9%
CV ROIC (from historical)
7.58%
CV NOPLAT = $10,098M
Tax rate / Op cash / Shares
Forecast tax: -3.5%
Op cash %: 3.0%
Shares: 5,683M
5-year consensus forecast
YearRevenue ($M)EBITDA ($M)
2025 61,936 18,264
2026 61,774 18,216
2027 59,231 17,466
2028 54,752 16,145
2029 53,164 15,677
Validation: set your view's WACC = 5.17%, cv_g = -1.61%, tax = -3.5%. Your model should produce exactly $24.17.

Your view

Yellow cells are editable.

Your model output

Model share price: $9.15
vs market: -62.1%
Enterprise value: $119,309M
Operating value: $98,513M
Continuing value: $56,038M
Debt: $66,993M
Excess cash: $18,568M
Residuals: B/S 0.0M · TFI 0.0M · TII 0.0M · CFI 0.0M

Forecast ratios (yellow cells)

Held constant across forecast years (H–M). Defaults are the most recent historical ratio. Override to express a different view (margin compression, working-capital efficiency, etc.).

Income statement

D&A % of revenue 11.02%
Non-op losses % of rev 0.00%

Working capital

AR % of revenue 23.22%
Unbilled rev % of rev 0.00%
Inventory % of rev 17.05%
Other CA % of rev 6.68%
AP % of rev 8.85%
Other ST liab % of rev 47.24%

Long-term assets & liab

LT investments % of rev 3.50%
Net fixed assets % of rev 24.76%
Other LT assets % of rev 33.20%
Other LT liab % of rev 34.91%

Consensus forecast (your editable copy)

Defaults are FMP analyst consensus. Edit any cell; Recalculate uses these values.

YearRevenue ($M)EBITDA ($M) EBITDA marginYoY rev growth
2025 29.5% —
2026 29.5% -0.3%
2027 29.5% -4.1%
2028 29.5% -7.6%
2029 29.5% -2.9%
CV NOPLAT: $10,098M · CV ROIC: 7.58%

Sensitivity: model price by WACC × cv_g

5×5 grid centered on your assumptions. Green cells > market, red < market. Computes 25 model runs (~10s).

Click “Run sensitivity” above.

Monte Carlo simulation

Sample WACC, cv_g, revenue multiplier, and EBITDA margin shift; see distribution of fair value.

Distribution widths (σ):
Each sample: draws values from normal distributions centered on your current assumptions, runs the full DCF, records the model price. 100 samples ≈ 60s.

Configure σ above and click “Run Monte Carlo”.

Peers (LLM-proposed comparables)

3–5 publicly-traded comps with rationale + suggested multiples. ~$0.002/call, cached 30d.

▸ expand

Red flags (accounting / governance / operational / liquidity)

Severity-tiered concerns with explicit evidence. ~$0.004/call, cached 30d.

▸ expand

Recent news (web search)

Material items from the last 60 days with source links. ~$0.02–0.05/call, cached 6h.

▸ expand

Snapshots

No saved snapshots yet.